| Literature DB >> 34989138 |
Caterina Maffeis1, Andrea Rossi1, Lorenzo Cannata2, Camilla Zocco2, Evgeny Belyavskiy3, Aravind Kumar Radhakrishnan3, Anna Feuerstein3, Daniel Armando Morris3,4,5, Elisabeth Pieske-Kraigher3,4,5, Burkert Pieske3,4,6,5, Frank Edelmann3,4,5, Pier Luigi Temporelli2.
Abstract
AIMS: We hypothesized that left atrial (LA) remodelling and function are associated with poor exercise capacity as prognostic marker in chronic heart failure (CHF) across a broad range of left ventricular ejection fraction (LVEF). METHODS ANDEntities:
Keywords: Cardiopulmonary exercise test; Ejection fraction; Exercise capacity; Heart failure; Left atrial strain; Prognosis
Mesh:
Year: 2022 PMID: 34989138 PMCID: PMC8934969 DOI: 10.1002/ehf2.13788
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Demographic, clinical, and echocardiographic characteristics in the overall population and according to exercise capacity < 14 or ≥14 mL/kg/min; P‐value for comparison of each variable between the two groups (peak VO2 < 14 or ≥14 mL/kg/min); P‐value for Pearson's correlation between each variable and linear peak VO2 in the overall population
| Overall population ( | Peak VO2 < 14 mL/kg/min ( | Peak VO2 ≥ 14 mL/kg/min ( |
|
| |
|---|---|---|---|---|---|
| Age, years | 65 ± 11 | 68 ± 10 | 63 ± 11 | 0.001 | 0.002 |
| Male sex, | 136 (80) | 59 (77) | 77 (82) | 0.4 | 0.4 |
| Body mass index, kg/m2 | 27 ± 5 | 28 ± 5 | 26 ± 4 | 0.01 | 0.003 |
| NYHA class III, | 23 (13) | 18 (23) | 5 (5) | <0.0001 | <0.0001 |
| Hypertension, | 105 (61) | 48 (62) | 57 (61) | 0.6 | 0.8 |
| Hypercholesterolaemia, | 79 (46) | 37 (48) | 42 (42) | 0.7 | 0.7 |
| Diabetes, | 36 (21) | 17 (22) | 19 (20) | 0.7 | 0.7 |
| Ischaemic heart disease, | 93 (54) | 45 (58) | 48 (51) | 0.4 | 0.4 |
| Atrial fibrillation, | 30 (18) | 21 (27) | 9 (10) | 0.004 | 0.003 |
| Haemoglobin, g/dL | 13.4 ± 1.6 | 13.1 ± 1.6 | 13.6 ± 1.6 | 0.05 | 0.003 |
| Creatinine, mg/dL | 1.1 ± 0.4 | 1.2 ± 0.4 | 1.1 ± 0.3 | 0.01 | <0.0001 |
| NT‐proBNP, pg/mL | 1473 ± 1962 | 1900 ± 2355 | 1055 ± 1382 | 0.03 | 0.002 |
| Loop diuretics, | 134 (78) | 70 (91) | 64 (68) | <0.0001 | <0.0001 |
| Beta‐blockers, | 145 (85) | 69 (90) | 76 (81) | 0.2 | 0.1 |
| ACE inhibitors, | 121 (71) | 45 (58) | 76 (81) | 0.005 | 0.02 |
| Mineralocorticoid receptor antagonists, | 41 (24) | 16 (21) | 25 (26) | 0.5 | 0.6 |
| SBP, mmHg | 120 ± 22 | 117 ± 22 | 124 ± 23 | 0.05 | 0.003 |
| HR at rest, b.p.m. | 68 ± 11 | 67 ± 9 | 69 ± 11 | 0.3 | 0.6 |
| Peak VO2, mL/kg/min | 16 ± 11 | 11.4 ± 1.8 | 18.5 ± 3.6 | <0.0001 | — |
| % predicted peak VO2 | 66 ± 21 | 55 ± 18 | 76 ± 20 | <0.0001 | <0.0001 |
| Peak RER | 1.09 ± 0.08 | 1.08 ± 0.08 | 1.09 ± 0.08 | 0.2 | 0.9 |
| VE/VCO2 slope | 37 ± 8 | 40.5 ± 9.4 | 33.6 ± 6.0 | <0.0001 | <0.0001 |
| LV EDVi, mL/m2 | 85 ± 36 | 88 ± 35 | 83 ± 36 | 0.4 | 0.01 |
| LVMi, g/m2 | 120 ± 31 | 122 ± 29 | 119 ± 32 | 0.5 | 0.08 |
| LVEF, % | 42 ± 16 | 38 ± 17 | 44 ± 18 | 0.01 | <0.0001 |
| LVGLS, % | −11.6 ± 6.1 | −9.8 ± 6.2 | −12.9 ± 5.9 | 0.001 | <0.0001 |
| SV‐LVOT‐i, mL/m2 | 29 ± 7 | 27 ± 6 | 32 ± 7 | 0.008 | 0.1 |
| Diastolic dysfunction | 156 (91%) | 72 (94%) | 84 (89%) | 0.1 | 0.07 |
| I degree | 39 (23%) | 16 (21%) | 23 (24%) | ||
| II degree | 36 (21%) | 22 (29%) | 14 (15%) | ||
| III degree | 23 (13%) | 11 (14%) | 12 (13%) | ||
| Indeterminate | 58 (34%) | 23 (30%) | 35 (37%) | ||
| LAVi, mL/m2 | 48 ± 21 | 53 ± 24 | 44 ± 18 | 0.005 | 0.002 |
| LA reservoir strain, % | 16 ± 9 | 12 ± 5 | 20 ± 10 | <0.0001 | <0.0001 |
| LA conduit strain, % | 9 ± 5 | 7 ± 3 | 11 ± 5 | <0.0001 | <0.0001 |
| LA contractile strain, % | 9 ± 5 | 6 ± 3 | 10 ± 5 | <0.0001 | <0.0001 |
| E, cm/s | 77 ± 25 | 83 ± 28 | 74 ± 23 | 0.05 | 0.1 |
| A, cm/s | 66 ± 24 | 66 ± 26 | 66 ± 22 | 0.9 | 0.9 |
| E/A | 1.4 ± 0.9 | 1.5 ± 1.1 | 1.3 ± 0.9 | 0.2 | 0.1 |
| E/e′ | 12.4 ± 5.1 | 12.8 ± 4.6 | 12.1 ± 5.6 | 0.5 | 0.08 |
| MR, | 136 (80) | 62 (81) | 74 (79) | 0.6 | 0.6 |
| TR, | 120 (70) | 61 (79) | 59 (63) | 0.01 | 0.01 |
| SPAP, mmHg | 35 ± 12 | 38 ± 13 | 32 ± 9 | 0.01 | 0.001 |
| TAPSE, mm | 20 ± 5 | 18 ± 5 | 21 ± 4 | <0.0001 | <0.0001 |
| TAPSE/SPAP, mm/mmHg | 0.60 ± 0.24 | 0.51 ± 0.22 | 0.68 ± 0.23 | <0.0001 | <0.0001 |
EDVi, end‐diastolic volume indexed to body surface area; HR, heart rate; LAVi, left atrial volume indexed to body surface area; LV, left ventricular; LVEF, left ventricular ejection fraction (biplane); LVGLS, left ventricular global longitudinal strain (biplane); LVMi, left ventricular mass indexed to body surface area; MR, mitral regurgitation; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; RER, respiratory exchange ratio; SBP, systolic blood pressure; SPAP, systolic pulmonary artery pressure; SV‐LVOT‐i, stroke volume measured at left ventricular outflow tract indexed to body surface area; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VE/VCO2, minute ventilation/carbon dioxide production ratio; VO2, oxygen consumption.
Linear regression analysis for association between LA parameters, clinical or other echocardiographic variables, and peak VO2 (mL/kg/min): P‐value, b coefficient (95% confidence interval)
| LA reservoir strain, % | LA contractile strain, % | LA conduit strain, % | LA volume index, mL/m2 | |
|---|---|---|---|---|
| Univariate | <0.0001; 0.21 (0.14–0.28) | <0.0001; 0.29 (0.16–0.44) | <0.0001; 0.32 (0.18–0.46) | 0.002; −0.05 (−0.08 to −0.02) |
| Model 1 | <0.0001; 0.22 (0.12–0.31) | 0.001; 0.33 (0.15–0.52) | <0.0001; 0.35 (0.17–0.53) | 0.1; −0.03 (−0.09 to 0.01) |
| Model 2 | <0.0001; 0.16 (0.08–0.24) | 0.003; 0.23 (0.08–0.37) | 0.007; 0.20 (0.06–0.35) | 0.06; −0.03 (−0.06 to 0.001) |
LA, left atrial; VO2, oxygen consumption.
Model 1: adjusted for age, body mass index, New York Heart Association class, atrial fibrillation/sinus rhythm, haemoglobin, and creatinine. Model 2: adjusted for left ventricular ejection fraction and tricuspid annular plane systolic excursion.
Figure 1Linear correlations between left atrial strain and peak VO2 values in the overall study population.
Figure 2Receiver‐operating characteristic curves analysis of the parameters with the greatest value of area under the curve (AUC). LA, left atrial; LVGLS, left ventricular global longitudinal strain; TAPSE, tricuspid annular plane systolic excursion.
Figure 3Distribution of left atrial volume index and left atrial reservoir function values in patients with peak VO2 < 14 (red dots) or ≥14 mL/kg/min (blue dots).
Figure 4Prevalence of patients with normal/dilated left atrial volume (LAVi) and normal/reduced left atrial reservoir strain in patients with peak VO2 < 14 or ≥14 mL/kg/min.
Association between exercise capacity (pVO2, mL/kg/min) and key echocardiographic parameters in patients with HFrEF, HFmrEF, and HFpEF
| HFrEF ( | HFmrEF ( | HFpEF ( | ||||
|---|---|---|---|---|---|---|
| Mean ± SD |
| Mean ± SD |
| Mean ± SD |
| |
| LA reservoir strain, % | 14 ± 9 | 0.003 | 19 ± 8 | 0.04 | 18 ± 9 | 0.01 |
| LAVi, mL/m2 | 54 ± 22 | 0.1 | 41 ± 16 | 0.04 | 44 ± 20 | 0.8 |
| LVEF, % | 28 ± 7 | 0.002 | 45 ± 3 | 0.1 | 62 ± 6 | 0.08 |
| LVGLS, % | −7 ± 2 | 0.002 | −13 ± 3 | 0.06 | −19 ± 3 | 0.1 |
| TAPSE, mm | 19 ± 5 | 0.002 | 19 ± 4 | 0.6 | 20 ± 4 | 0.01 |
HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LA, left atrial; LAVi, left atrial volume indexed to body surface area; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; pVO2, maximal oxygen consumption; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion.
Adjusted for age and body mass index.
Figure 5Box plots of left atrial (LA) reservoir strain and left ventricular (LV) global longitudinal strain in patients with heart failure with reduced ejection fraction (A), mid‐range ejection fraction (B), and preserved ejection fraction (C).